In order to determine if the in vitro anti-oxidant effects of rosiglitazone could be translated to an in vivo model of PD, first any alterations in PPARγ levels in the substantia nigra pars compacta (SNpc), the main area of neuron loss in PD, were examined by western blot and qPCR analysis. Here, PPARG is linked to Parkinson disease.